Back to Search Start Over

Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.

Authors :
Lee JY
Lensing SY
Berry-Lawhorn JM
Jay N
Darragh TM
Goldstone SE
Wilkin TJ
Stier EA
Einstein M
Pugliese JC
Palefsky JM
Source :
Contemporary clinical trials [Contemp Clin Trials] 2022 Feb; Vol. 113, pp. 106679. Date of Electronic Publication: 2022 Jan 10.
Publication Year :
2022

Abstract

It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV. To address these concerns, the AIDS Malignancy Consortium completed a large-scale, randomized trial to compare strategies for the prevention of anal cancer among PLWH with anal HSIL. The objective of the study was to determine whether treating anal HSIL was effective in reducing the incidence of anal cancer in PLWH compared with active monitoring. This paper describes the design of the ANal Cancer/HSIL Outcomes Research Study (ANCHOR) with respect to estimating the anal cancer event rate in this high risk population.<br /> (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1559-2030
Volume :
113
Database :
MEDLINE
Journal :
Contemporary clinical trials
Publication Type :
Academic Journal
Accession number :
35017115
Full Text :
https://doi.org/10.1016/j.cct.2022.106679